Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
prolong ejaculation.
Popular Articles

New Diagnostic Method For Gout: Dual Energy Computed Tomography Instead Of Joint Aspiration
The most reliable method of diagnosing gout is to aspirate the joint in order to obtain fluid
generic viagra
What Is Narcolepsy? What Causes Narcolepsy?
Narcolepsy - from the French narcolepsie, which was derived from the Greek narke meaning numbness and lepsis meaning attack or seizure - is a chronic sleep disorder where the brain is unable to regulate the body"s sleep-wake cycles. People with narcolepsy may feel an overwhelming urge to sleep at various points in the day, and they will often fall asleep spontaneously for a few seconds to a few minutes. In extreme cases, narcoleptics (people with narcolepsy) will remain asleep for over an hour.
News of the day
Printing New Organs: Foundation Funds Medical Technology That Replicates Human Tissue
Methuselah Foundation has identified Organovo, Inc. as a leader in the extraordinary science of bio-printing. The US Department of Health and Human Services predicts: "Within 20 years regenerative medicine will be the standard of care for replacing all tissue/organ systems in the body." Organovo, with the support of Methuselah Foundation, is applying its breakthrough organ printing technologies to make that prediction a reality.
Public Health

Prospect Therapeutics, Inc.'s GCS-100 Inhibited Blood Vessel Formation In A Variety Of Cancer Models

Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that there has been promising initial interest from pharma companies in the intellectual property of Prospect Therapeutics, Inc. ("Prospect"). In preclinical studies, GCS-100 inhibited blood vessel formation in a variety of cancer models. Development and growth of solid tumors requires new blood vessel growth, or angiogenesis, to deliver oxygen and nutrients to a tumor. Galectin-3 also plays an important role in stimulating angiogenesis in a variety of tissues. The intellectual property, regulatory dossier, fixed assets and clinical inventory will be sold at auction on Monday, June 29, 2009 at 12:00 noon. Persons interested in bidding must sign a Confidentiality Agreement ("CA") obtained from Finn"s Office - jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package. About Prospect Therapeutics, Inc. Prospect"s lead product candidate, GCS-100, is a carbohydrate molecule designed to inhibit the activity of Galectin-3, a protein found in high concentration in a broad range of human cancers and whose over-expression is associated with poor prognosis in cancer patients. Joseph F. Finn, Jr., C.P.A.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009